Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis Reports Fourth Quarter and Full Year 2017 Financial Results

SPINRAZA launch one of the most successful in rare disease history FY 2017 GAAP operating income of $25M; FY 2017 pro forma operating income of $111M 2017 year-end cash over $1B Mid-2018 launches planned for inotersen and volanesorsen Conference call and webcast today, February 27, 2018, at 11:30